News

Mr Jackson joined Celator in October 2007 as head of commercial development. Mr Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of

Drospirenone and ethinyl estradiol product is a generic version of Yasmin, an oral contraceptive product manufactured and marketed by Bayer Schering Pharma. Yasmin is a 28-day oral contraceptive

Under the terms of the agreement, SomaLogic will receive committed research funding and will be entitled to receive a royalty on any marketed products developed as a result

The Court of Appeal pointed that the National Institute for Health and Clinical Excellence’s (NICE’s) refusal to allow Pfizer and Eisai full access to a computer model used

The final purchase price consisted of approximately $143.9 million, and approximately 1.8 million shares of Inverness series B convertible perpetual preferred stock. In addition, existing options to purchase

Under the terms of the agreement, Invitrogen will have the right to work with karyotypically normal human embryonic stem cells (hESCs) to develop novel research and drug discovery

The orphan drug designation provides eligibility for a seven-year period of market exclusivity in the US after product approval, an accelerated review process, grant funding, tax benefits and

Under the terms of the acquisition agreement, Cytogen shareholders will receive $0.62 per share, valuing the company at $22.6 million. To meet the consideration, Eusa has raised over

Under the terms of the collaboration, Cytopia has out-licensed specific proprietary technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers. Under